Skip to main content
Clover Biopharmaceuticals, Ltd. logo

Clover Biopharmaceuticals, Ltd. — Investor Relations & Filings

Ticker · 2197 HKEX Manufacturing
Open in API
Filings indexed 213 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2197

About Clover Biopharmaceuticals, Ltd.

http://www.cloverbiopharma.com

Clover Biopharmaceuticals, Ltd. is a global commercial-stage biotechnology company specializing in the research, development, manufacturing, and commercialization of innovative vaccines and biotherapeutic candidates. The company's core mission is to improve global health outcomes by addressing significant unmet medical needs, including infectious diseases, cancer, and autoimmune conditions. Clover utilizes its proprietary Trimer-Tag technology platform, which facilitates the development of stabilized trimeric protein antigens and biologics. Supported by in-house manufacturing and commercial infrastructure, Clover focuses on delivering its innovative pipeline products to populations worldwide.

Recent filings

Filing Released Lang Actions
Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Regulatory Filings Classification · 1% confidence The document is a notification letter to non-registered shareholders regarding the electronic dissemination of corporate communications and includes a reply form for language/format elections. It is not a financial report (annual, interim, earnings), nor a solicitation of proxies for a specific meeting, nor any of the specialized filings (e.g., M&A, dividends, director dealings). This falls into the general regulatory announcement/fallback category.
2026-04-23 English
2025 Annual Report
Annual Report Classification · 1% confidence The document is clearly identified as an 'ANNUAL REPORT 2025' for Clover Biopharmaceuticals, Ltd. It contains comprehensive sections including a company profile, corporate information, financial highlights, management discussion and analysis (MDA), and audited financial statements (Consolidated Statement of Profit or Loss, etc.). It is not an announcement of a report, but the full report itself, and it contains substantive financial data, fitting the definition of an Annual Report (10-K). FY 2025
2026-04-23 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended March 31, 2026
Share Issue/Capital Change Classification · 1% confidence The document is a mandatory monthly return to the Hong Kong Exchange under Chapter 19B of the Listing Rules covering movements in authorised share capital, issued shares, treasury shares and share option exercises. It is not an annual, interim or earnings report but rather a regulatory announcement of capital changes (share issues/options). This aligns with the “Share Issue/Capital Change (SHA)” category.
2026-04-09 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO INSIDE INFORMATION
Regulatory Filings Classification · 1% confidence The document is a supplemental announcement under Hong Kong Listing Rules detailing payment terms of a settlement agreement (inside information disclosure). It is not an earnings release, financial report, or formal annual/interim report, nor does it announce dividends, share issues, M&A, or management changes. Rather, it is a regulatory disclosure made pursuant to Listing Rule 13.09, serving as a general regulatory announcement about inside information. Therefore, it falls into the fallback category “Regulatory Filings” (RNS).
2026-04-02 English
Voluntary Announcement Clover Completes Enrollment in Australian Phase 2 Clinical Trial for RSV + hMPV + PIV3 Respiratory Combination Vaccine Candidates
Regulatory Filings Classification · 1% confidence The document is a voluntary business update announcement by the Board regarding completion of enrollment in a clinical trial. It does not report financial results, share issues, dividends, or management changes, nor is it a report publication notice. It is a general regulatory announcement of corporate developments, fitting the fallback “Regulatory Filings” category.
2026-03-30 English
GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUs PURSUANT TO THE RSU SCHEME
Director's Dealing Classification · 1% confidence The document is a formal stock exchange announcement of equity incentive awards—specifically the grant of share options and RSUs—to company directors and employees, including detailed tables of directors’ allocations under the Post-IPO Share Option Plan and RSU Scheme and related Listing Rules disclosures. These grants constitute personal share transactions by executives under the Listing Rules. Thus, it falls under the category for Director’s Dealing.
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.